BioCentury
ARTICLE | Company News

Oscient, Pfizer deal

February 13, 2006 8:00 AM UTC

OSCI acquired expanded rights to ramoplanin from PFE subsidiary Vicuron Pharmaceuticals Inc. OSCI, which already had North American rights, now has worldwide rights to the macrocyclic depsipeptide i...